Skip to main content

2024 ISPE Annual Meeting Main banner

Gastrointestinal conditions and treatments

Gastrointestinal conditions and treatments

Type here to filter the list

(043) “Effect Of Pharmacological Interventions On Liver Function Parameters In Patients With NAFLD/NASH: A Systematic Review and Network meta-Analysis”

Favorite
(044) A Comprehensive Meta-Analysis Assessing the Diagnostic Accuracy of Non-invasive Markers to Discriminate NAFLD and NASH

Favorite
(045) Assessment of Readiness to Change in Individuals with Alcoholic Liver Disease: A Cross-Sectional Study in Indian Settings

Favorite
(046) Associations between Laboratory Results and Mortality in Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Diabetes and Antihypertensive Drug Status.

Favorite
(047) Characteristics and prevalence of potential inappropriate proton-pump-inhibitors users among older adults in Portugal: A nationwide retrospective study

Favorite
(048) Cirrhosis Risk Prediction in individuals with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Favorite
(050) Compared to Thiopurines and Tumor Necrosis Factor Inhibitors Novel Biologics Are Associated with Reduced Risk of Non-Melanoma Skin Cancer Among Patients with Inflammatory Bowel Disease

Favorite
(051) Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: Impact of Study Design Differences on Treatment Effect

Favorite
(052) Drug Repurposing in Crohn’s Disease using Danish real-world data

Favorite
(053) Identification of Cohorts for Ulcerative Colitis, Diabetes, and Small Cell Lung Cancer With Corresponding Demographic and Geographic Distributions From a Nationally Representative U.S. Pharmacy Database

Favorite
(054) Incidence Rates of Severe Acute Liver Injury Associated with Hepatotoxic Medication Combinations: Approach to Inform Future Drug-Drug Interaction Studies

Favorite
(055) Measuring the Use of TNF-alpha Inhibitors in Patients with Ulcerative Colitis: Optimization of Washout Period Duration and Observability

Favorite
(056) Non-Alcoholic Steatohepatitis (NASH) as a Risk Factor in Hepatocellular Carcinoma (HCC) Development

Favorite
(057) Spatial-Temporal Patterns In Biologic Prescriptions For Inflammatory Bowel Diseases In The Public Healthcare System In Brazil

Favorite
(058) Surgery for Chronic Diverticular Disease - Incidence and Predictors

Favorite
(059) The Incidence of Immune Checkpoint Inhibitor-Related Hepatotoxicity (ICH) in a Real-World Setting: A Retrospective Cohort Study

Favorite